Latamoxef

Latamoxef
Clinical data
Routes of; administration	Intramuscular, intravenous
ATC code	J01DD06 (WHO) ;
Pharmacokinetic data
Protein binding	35 to 50%
Metabolism	Nil
Elimination half-life	2 hours
Excretion	Mostly renal, unchanged; also biliary
Identifiers
	IUPAC name (6R,7R)-7-{[3-hydroxy-2-(4-hydroxyphenyl)-3-; oxopropanoyl]amino}-7-methoxy-3-[(1-methyltetrazol-; 5-yl)sulfanylmethyl]-8-oxo-5-oxa-1-azabicyclo[4.2.0]; oct-2-ene-2-carboxylic acid;
CAS Number	64952-97-2;
PubChem CID	47499;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C20H20N6O9S
Molar mass	520.474 g/mol

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Latamoxef (or moxalactam) is an oxacephem antibiotic usually grouped with the cephalosporins. In oxacephems such as latamoxef, the sulfur atom of the cephalosporin core is replaced with an oxygen atom.

Latamoxef has been associated with prolonged bleeding time, and several cases of coagulopathy, some fatal, were reported during the 1980s.^[1]^[2] Latamoxef is no longer available in the United States.

References

↑ Weitekamp MR, Aber RC (1983). "Prolonged bleeding times and bleeding diathesis associated with moxalactam administration". JAMA. 249 (1): 69–71. PMID 6217353.
↑ Brown RB, Klar J, Lemeshow S, Teres D, Pastides H, Sands M (1986). "Enhanced bleeding with cefoxitin or moxalactam. Statistical analysis within a defined population of 1493 patients". Arch Intern Med. 146 (11): 2159–64. PMID 3778044.

[1] Weitekamp MR, Aber RC (1983). "Prolonged bleeding times and bleeding diathesis associated with moxalactam administration". JAMA. 249 (1): 69–71. PMID 6217353.

[2] Brown RB, Klar J, Lemeshow S, Teres D, Pastides H, Sands M (1986). "Enhanced bleeding with cefoxitin or moxalactam. Statistical analysis within a defined population of 1493 patients". Arch Intern Med. 146 (11): 2159–64. PMID 3778044.

[1]

[2]

v t e Antibacterials: cell wall disruption (J01C-J01D)
Internal to membrane/ (inhibit peptidoglycan subunit synthesis and transport)	Template:Navbox subgroup
Glycopeptide/ (inhibit PG chain elongation)	Vancomycin # (Oritavancin, Telavancin) · Teicoplanin (Dalbavancin) · Ramoplanin
Beta-lactams/ (inhibit cross-links with PBP)	Template:Navbox subgroup
Other	Template:Navbox subgroup
# = WHO-EM

Clinical data

Routes of administration	Intramuscular, intravenous
ATC code	J01DD06 (WHO)
Pharmacokinetic data
Protein binding	35 to 50%
Metabolism	Nil
Elimination half-life	2 hours
Excretion	Mostly renal, unchanged; also biliary
Identifiers
IUPAC name (6R,7R)-7-{[3-hydroxy-2-(4-hydroxyphenyl)-3- oxopropanoyl]amino}-7-methoxy-3-[(1-methyltetrazol- 5-yl)sulfanylmethyl]-8-oxo-5-oxa-1-azabicyclo[4.2.0] oct-2-ene-2-carboxylic acid
CAS Number	64952-97-2
PubChem CID	47499
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C₂₀H₂₀N₆O₉S
Molar mass	520.474 g/mol

Latamoxef

Overview

References

Navigation menu

Search